Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$6.85
-3.5%
$6.29
$3.80
$12.70
$29.74M-0.8418,296 shs7,933 shs
OpGen, Inc. stock logo
OPGN
OpGen
$4.69
-0.2%
$4.56
$0.53
$5.25
$47.22M-1.689,867 shs2,623 shs
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
$6.48
-1.2%
$8.23
$6.25
$33.73
$46.58M0.8420,197 shs1,732 shs
Renalytix Plc stock logo
RNLX
Renalytix
$0.21
$0.23
$0.18
$2.40
$17.18M2.721.45 million shs934,496 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
+1.07%-4.62%-4.18%+61.40%+2.69%
OpGen, Inc. stock logo
OPGN
OpGen
-0.21%+3.30%-4.48%+581.29%+77.66%
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
-0.91%-6.69%-20.10%-28.54%-76.57%
Renalytix Plc stock logo
RNLX
Renalytix
0.00%0.00%0.00%0.00%-54.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
1.3499 of 5 stars
0.05.00.00.02.01.70.6
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/AN/AN/AN/A
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
1.2696 of 5 stars
3.32.00.00.00.00.80.6
Renalytix Plc stock logo
RNLX
Renalytix
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
0.00
N/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
0.00
N/AN/AN/A
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
2.50
Moderate Buy$16.25150.77% Upside
Renalytix Plc stock logo
RNLX
Renalytix
3.00
Buy$3.001,348.58% Upside

Current Analyst Ratings Breakdown

Latest RNLX, PIII, OPGN, and CCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/21/2025
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $20.00
(Data available from 6/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
$383.96M0.08N/AN/A$56.67 per share0.12
OpGen, Inc. stock logo
OPGN
OpGen
$2.67M17.66N/AN/A($11.55) per share-0.41
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
$1.49B0.03$2.79 per share2.32$0.45 per share14.40
Renalytix Plc stock logo
RNLX
Renalytix
$2.29M7.50N/AN/A($0.10) per share-2.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
-$41.93MN/A0.00N/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
-$32.67MN/A0.00N/A-1,140.36%N/A-287.58%7/7/2025 (Estimated)
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
-$57.77M-$47.28N/AN/AN/A-6.95%-71.31%-11.93%8/6/2025 (Estimated)
Renalytix Plc stock logo
RNLX
Renalytix
-$33.46M-$0.39N/AN/A-1,461.60%N/A-281.40%N/A

Latest RNLX, PIII, OPGN, and CCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
-$5.00-$6.28-$1.28-$6.28$362.09 million$373.23 million
3/27/2025Q4 2024
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
-$8.50-$16.00-$7.50-$0.36$378.88 million$370.69 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/AN/AN/AN/AN/A
OpGen, Inc. stock logo
OPGN
OpGen
N/AN/AN/AN/AN/A
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
N/AN/AN/AN/AN/A
Renalytix Plc stock logo
RNLX
Renalytix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
1.15
0.47
0.46
OpGen, Inc. stock logo
OPGN
OpGen
N/A
5.45
5.45
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
1.11
0.53
0.53
Renalytix Plc stock logo
RNLX
Renalytix
N/A
0.53
0.53

Institutional Ownership

CompanyInstitutional Ownership
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
N/A
OpGen, Inc. stock logo
OPGN
OpGen
2.68%
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
7.75%
Renalytix Plc stock logo
RNLX
Renalytix
9.92%

Insider Ownership

CompanyInsider Ownership
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
46.50%
OpGen, Inc. stock logo
OPGN
OpGen
43.80%
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
17.79%
Renalytix Plc stock logo
RNLX
Renalytix
18.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Concord Medical Services Holdings Limited stock logo
CCM
Concord Medical Services
9704.34 million2.32 millionNot Optionable
OpGen, Inc. stock logo
OPGN
OpGen
10010.07 million4.70 millionNot Optionable
P3 Health Partners Inc. stock logo
PIII
P3 Health Partners
5007.19 million294.74 millionNot Optionable
Renalytix Plc stock logo
RNLX
Renalytix
10082.96 million63.06 millionOptionable

Recent News About These Companies

Renalytix Adjusts Share Capital Amid Fundraising Shortfall
Renalytix AI earnings: here's what Wall Street expects

Media Sentiment Over Time

Concord Medical Services stock logo

Concord Medical Services NYSE:CCM

$6.85 -0.25 (-3.52%)
As of 12:18 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.

OpGen stock logo

OpGen NASDAQ:OPGN

$4.69 -0.01 (-0.21%)
As of 06/9/2025 09:30 AM Eastern

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

P3 Health Partners stock logo

P3 Health Partners NASDAQ:PIII

$6.48 -0.08 (-1.22%)
As of 12:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.

Renalytix stock logo

Renalytix NASDAQ:RNLX

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.